Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...
News Medical on MSN16h
New biomarker could help predict Parkinson’s disease progressionA team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
El Mundo on MSN5h
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming yearsSome are small; others, biological, and there are also medications ... that future treatment will consist of a combination of ...
Consisting of five separate booklets, the World Drug Report 2021 provides an in-depth analysis of the global drug markets and paints a comprehensive picture of the measurable effects and potential ...
Molson Coors Beverage Co. Cl B $61.89 1.39 2.30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback